ZURICH Roche said on Tuesday that European regulators approved its drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukemia, boosting the Swiss group's line-up of new cancer treatments.
The new medicine is an improved follow-on medicine to the Swiss drugmaker's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.
The move endorses a favorable recommendation in May from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP), which are normally followed by the European Commission.
(Reporting By Katharina Bart)
Major depression is increasingly recognized as a serious U.S. health problem. Experts are trying to identify at-risk children and adults and treat depression in its earliest stages.